Akebia Therapeutics (AKBA) Current Leases (2013 - 2020)
Akebia Therapeutics' (AKBA) quarterly Current Leases came in at $5.1 million in Q1 2020, down 83.72% year-on-year from $31.3 million in Q2 2019, and up 2.14% on a QoQ basis from $5.0 million in Q4 2019.
Akebia Therapeutics (AKBA) Current Leases (2013 - 2020) Analysis & Trends
Akebia Therapeutics (AKBA) has 4 years of Current Leases data on file, last reported at $5.1 million in Q1 2020.
- On a quarterly basis, Current Leases fell 83.72% year-over-year to $5.1 million in Q1 2020; TTM through Mar 2020 was $5.1 million, a 83.72% decrease from a year earlier, with the FY2019 full-year figure at $5.0 million, changed N/A from the prior year.
- Current Leases for Q1 2020 stood at $5.1 million, up from $5.0 million in the prior quarter.
- Over the last five years, Current Leases for AKBA reached as high as $31.3 million in Q1 2019 and fell as low as $4.8 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 5.10 Mn |
| Dec 31, 2019 | 4.99 Mn |
| Sep 30, 2019 | 4.88 Mn |
| Jun 30, 2019 | 4.78 Mn |
| Mar 31, 2019 | 31.30 Mn |
| Jun 30, 2014 | 3,939.00 |
| Mar 31, 2014 | 3,911.00 |
| Dec 31, 2013 | 3,912.00 |